## Lunit Teams Up with VIDI Group to Enhance Breast Cancer Screening in France with AI
South Korea-based Lunit, a renowned developer of AI-powered solutions for cancer diagnosis and treatment, has announced a strategic alliance with VIDI Group, France’s leading private radiology and radiotherapy network. This collaboration aims to expand the reach of Lunit’s innovative AI solution, Lunit INSIGHT MMG, across VIDI’s extensive network of over 400 sites and 1,200 doctors.
This partnership signifies a significant advancement in enhancing the efficiency and accuracy of breast cancer screening in France. VIDI’s network, encompassing nearly a quarter of the French private radiology market, will benefit from Lunit INSIGHT MMG’s advanced capabilities. This AI-powered solution has already proven its effectiveness within the VIDI network, with multiple members adopting it since 2021.
Dr. François Pey, a radiologist from Coradix in Perpignan, has praised Lunit INSIGHT MMG’s high specificity and user-friendly deployment capabilities. He stated, “Lunit INSIGHT MMG serves as an invaluable tool for radiologists, offering increased confidence by ensuring no detail is missed without escalating false positives. This reduces the need for additional spot views and certain ultrasounds, streamlining the patient journey.”
VIDI’s decision to formalize its partnership with Lunit, following successful real-world implementations, was announced at the recent JFR 2024 conference. Through this agreement, Lunit INSIGHT MMG will be recommended to all VIDI members, simplifying access and reinforcing VIDI’s commitment to innovative healthcare solutions.
Amélie Libessart, Managing Director of VIDI, expressed enthusiasm about the partnership, stating, “This collaboration aligns with VIDI’s strategy of promoting early adoption of innovative solutions that have been rigorously tested by our network members. The positive feedback received from our doctors and the demonstrable improvements in diagnostics and care solidify the value of AI in healthcare. In an environment where waiting times pose a significant public health challenge, leveraging AI to streamline patient care makes perfect sense.”
Brandon Suh, CEO of Lunit, highlighted the critical role of AI in combatting breast cancer. “With over 60,000 new breast cancer cases reported in mainland France in 2023, making it the leading cancer in women regarding incidence and mortality, the need for AI to support early detection and diagnosis is paramount,” he said. “Combining VIDI’s extensive network and dedication to medical excellence, we are confident that Lunit INSIGHT MMG will become an indispensable tool in the fight against breast cancer, enabling radiologists to detect anomalies that might otherwise be missed and ultimately, save more lives.”
Beyond this immediate partnership, Lunit aims to further expand its presence in the French market and explore wider collaboration opportunities with VIDI in education, communication, and product development, fostering continuous innovation in radiology.
About Lunit
Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company dedicated to conquering cancer. Their AI-powered medical image analytics and AI biomarkers aim to ensure accurate diagnoses and optimal treatment for every cancer patient. Lunit INSIGHT, their FDA-cleared suite for cancer screening, serves over 4,500 hospitals and medical institutions across 55+ countries. Their clinical studies have been published in leading journals, including the Journal of Clinical Oncology and The Lancet Digital Health, and presented at major global conferences like ASCO and RSNA. In 2024, Lunit acquired Volpara Health Technologies, setting the stage for exceptional synergy and accuracy, particularly in breast health and screening technologies. Headquartered in Seoul, South Korea, with a global network of offices, Lunit is at the forefront of the global fight against cancer. Learn more at lunit.io.
About VIDI
The VIDI network is a pioneer in French liberal radiology and radiotherapy. Through its independence, VIDI champions a medical project dedicated to improving the quality of care for all patients. Leveraging its national network, VIDI facilitates access to exceptional diagnostics and care, as well as specialist radiologists in all areas of expertise and radiotherapists, spread across France. The VIDI cooperative network comprises 400 medical imaging sites and over 1,200 radiologists and radiotherapists. All members are committed to delivering the most relevant and efficient medical imaging examinations throughout the care pathway, from screening to interventional procedures, diagnosis to treatment. For more information, visit www.groupe-VIDI.fr.
